Results 181 to 190 of about 3,379 (229)
Some of the next articles are maybe not open access.
Exclusive Real World Evidence Journal
Background: While Betahistine (48 mg/day) with Canalith Repositioning Maneuvers (CRMs) improves vertigo resolution in benign paroxysmal positional vertigo (BPPV), the optimal duration of therapy remains uncertain. Objective: To compare the effectiveness
V. Gupta +3 more
semanticscholar +1 more source
Background: While Betahistine (48 mg/day) with Canalith Repositioning Maneuvers (CRMs) improves vertigo resolution in benign paroxysmal positional vertigo (BPPV), the optimal duration of therapy remains uncertain. Objective: To compare the effectiveness
V. Gupta +3 more
semanticscholar +1 more source
Journal of Psychopharmacology
Background: Drugs for psychosis can cause weight gain and metabolic disorders in schizophrenia. Given its partial agonistic activity at histamine receptors, betahistine could shape the effects of drugs for psychosis on weight gain and food intake.
Najmeh Abbasi Jannatabadi +4 more
semanticscholar +1 more source
Background: Drugs for psychosis can cause weight gain and metabolic disorders in schizophrenia. Given its partial agonistic activity at histamine receptors, betahistine could shape the effects of drugs for psychosis on weight gain and food intake.
Najmeh Abbasi Jannatabadi +4 more
semanticscholar +1 more source
Expert Opinion on Drug Metabolism & Toxicology
Background Betahistine hydrochloride is critical for Ménière’s syndrome treatment. Validating bioequivalence of generic and reference formulations under fasting/postprandial conditions is key for clinical substitution.
Zhi-Xiang Pan +11 more
semanticscholar +1 more source
Background Betahistine hydrochloride is critical for Ménière’s syndrome treatment. Validating bioequivalence of generic and reference formulations under fasting/postprandial conditions is key for clinical substitution.
Zhi-Xiang Pan +11 more
semanticscholar +1 more source
Otology and Neurotology, 2023
Objective Betahistine has not been proven to be superior to placebo in the BEMED study, a multicenter, double-blind, randomized, placebo controlled trial.
L. Sutton, Reshma Ghedia, J. Harcourt
semanticscholar +1 more source
Objective Betahistine has not been proven to be superior to placebo in the BEMED study, a multicenter, double-blind, randomized, placebo controlled trial.
L. Sutton, Reshma Ghedia, J. Harcourt
semanticscholar +1 more source
Acta Oto-Laryngologica
Background Many studies have discussed the betahistine treatment for Meniere’s disease (MD). However, regarding cochlear MD, there is no consensus on the long-term betahistine treatment.
Ping-Chia Cheng +6 more
semanticscholar +1 more source
Background Many studies have discussed the betahistine treatment for Meniere’s disease (MD). However, regarding cochlear MD, there is no consensus on the long-term betahistine treatment.
Ping-Chia Cheng +6 more
semanticscholar +1 more source
GLC determination of betahistine in serum
Experientia, 1978A gas chromatographic method was developed for the determination of betahistine in serum in the range of 0.6-6.0 microgram/ml.
J F, Douglas, T L, Hohing
openaire +2 more sources
Betahistine mesylate reduces the damage of blue light exposure in Drosophila model.
Journal of Photochemistry and Photobiology. B: BiologyPrevious studies have demonstrated the efficacy of betahistine mesylate in treating vertigo and angioneurotic headache, enhancing microcirculation, and facilitating histamine release.
Xiang-Yu Li +3 more
semanticscholar +1 more source
Betahistine Exacerbates Amikacin Ototoxicity
Annals of Otology, Rhinology & Laryngology, 2014Objective: Betahistine augments cochlear blood flow and is currently used as an efficient therapeutic agent. Amikacin is used in a wide range of areas, but its ototoxic effect continues to be problematic. This study investigates the effect of betahistine on amikacin-induced ototoxicity.
AKSOY, Fadlullah +6 more
openaire +3 more sources
Acta Oto-Laryngologica, 1988
One hundred and seventeen adult patients suffering from vestibular vertigo were treated in a multicentre double-blind study with flunarizine (10 mg before sleeping) or betahistine dichlorhydrate (8 mg 3 times daily). The study took 2 months. The results revealed that flunarizine is significantly more active against attacks of vertigo and associated ...
openaire +1 more source
One hundred and seventeen adult patients suffering from vestibular vertigo were treated in a multicentre double-blind study with flunarizine (10 mg before sleeping) or betahistine dichlorhydrate (8 mg 3 times daily). The study took 2 months. The results revealed that flunarizine is significantly more active against attacks of vertigo and associated ...
openaire +1 more source